Report for: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Title	Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Published in	The Lancet, February 2021
DOI	10.1016/s0140-6736(21)00234-8
Pubmed ID	33545094
Authors	Denis Y Logunov, Inna V Dolzhikova, Dmitry V Shcheblyakov, Amir I Tukhvatulin, Olga V Zubkova, Alina S Dzharullaeva, Anna V Kovyrshina, Nadezhda L Lubenets, Daria M Grousova, Alina S Erokhova, Andrei G Botikov, Fatima M Izhaeva, Olga Popova, Tatiana A Ozharovskaya, Ilias B Esmagambetov, Irina A Favorskaya, Denis I Zrelkin, Daria V Voronina, Dmitry N Shcherbinin, Alexander S Semikhin, Yana V Simakova, Elizaveta A Tokarskaya, Daria A Egorova, Maksim M Shmarov, Natalia A Nikitenko, Vladimir A Gushchin, Elena A Smolyarchuk, Sergey K Zyryanov, Sergei V Borisevich, Boris S Naroditsky, Alexander L Gintsburg

View on publisher site Alert me about new mentions

Twitter Demographics

The data shown below were collected from the profiles of 42,082 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Geographical breakdown

Country	Count	As %
Mexico	5112	12%
Argentina	4044	10%
United States	1185	3%
Colombia	984	2%
Venezuela, Bolivarian Republic of	878	2%
Spain	804	2%
Chile	569	1%
Uruguay	475	1%
United Kingdom	432	1%
Other	6293	15%
Unknown	21306	51%

Demographic breakdown

Type	Count	As %
Members of the public	39536	94%
Scientists	1252	3%
Practitioners (doctors, other healthcare professionals)	771	2%
Science communicators (journalists, bloggers, editors)	512	1%
Unknown	11	<1%

Mendeley readers

The data shown below were compiled from readership statistics for 2,034 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
Unknown	2034	100%

Demographic breakdown

Readers by professional status	Count	As %
Student > Bachelor	318	16%
Researcher	250	12%
Student > Master	173	9%
Student > Ph. D. Student	156	8%
Other	115	6%
Other	395	19%
Unknown	627	31%

Readers by discipline	Count	As %
Medicine and Dentistry	493	24%
Biochemistry, Genetics and Molecular Biology	194	10%
Agricultural and Biological Sciences	101	5%
Immunology and Microbiology	88	4%
Pharmacology, Toxicology and Pharmaceutical Science	86	4%
Other	361	18%
Unknown	711	35%

Attention Score in Context

This research output has an Altmetric Attention Score of 26920. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 June 2023.

All research outputs

#12

of 23,954,688 outputs

Outputs from The Lancet

of 41,113 outputs

Outputs of similar age

of 509,791 outputs

Outputs of similar age from The Lancet

of 390 outputs

Altmetric has tracked 23,954,688 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.

So far Altmetric has tracked 41,113 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 67.8. This one has done particularly well, scoring higher than 99% of its peers.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 509,791 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.

We're also able to compare this research output to 390 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

About this Attention Score

Mentioned by

Citations

Readers on

Twitter Demographics

Geographical breakdown

Demographic breakdown

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context